CareDx (CDNA) Financials: History & Chart

CareDx, Inc(CDNA)

Medical - Diagnostics & Research · Brisbane, CA

$65.34-4.52 (-6.46%)

Delayed quote: Oct 6, 2026, 1:10 PM EDT

About CareDx, Inc

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.

Brisbane, CA

763 employees

www.caredx.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: John Walter Hanna Jr.

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	458.09M	131.95M	117.70M	108.39M	100.06M	86.68M	84.69M	86.58M	82.88M
Cost of Goods Sold	134.76M	34.97M	33.63M	35.51M	30.65M	28.66M	28.41M	28.18M	27.57M
Gross Profit	323.33M	96.98M	84.07M	72.87M	69.40M	58.02M	56.27M	58.40M	55.31M
Gross Profit Margin	70.6%	73.5%	71.4%	67.2%	69.4%	66.9%	66.4%	67.5%	66.7%
Total Operating Expenses	327.56M	96.72M	82.27M	78.91M	69.65M	68.79M	64.28M	-16.29M	65.80M
Research & Development	79.87M	22.38M	21.42M	19.31M	16.77M	16.83M	18.52M	16.53M	17.49M
Selling, General & Administrative	247.69M	74.35M	60.86M	59.61M	52.88M	51.96M	45.76M	61.76M	48.32M
Operating Income (EBIT)	-4.23M	257K	1.80M	-6.04M	-246K	-10.77M	-8.01M	74.69M	-10.49M
Operating Margin	-0.9%	0.2%	1.5%	-5.6%	-0.2%	-12.4%	-9.5%	86.3%	-12.7%
Income Before Tax (EBT)	115.19M	114.52M	2.78M	-3.76M	1.66M	-8.69M	-10.29M	78.18M	-7.21M
Interest Income	7.67M	1.74M	1.91M	2.01M	2.01M	2.36M	2.78M	3.05M	3.00M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	119.42M	114.26M	979K	2.28M	1.91M	2.09M	-2.28M	3.49M	3.28M
Net Income	111.01M	110.64M	2.81M	-4.11M	1.68M	-8.57M	-10.35M	78.01M	-7.41M
Income Tax Expense	4.18M	3.88M	-32K	345K	-15K	-117K	58K	171K	200K
Net Profit Margin	24.2%	83.8%	2.4%	-3.8%	1.7%	-9.9%	-12.2%	90.1%	-8.9%
EBITDA	15.56M	4.30M	7.12M	-780K	4.92M	-5.72M	-3.07M	79.38M	-5.60M
EBITDA Margin	3.4%	3.3%	6.0%	-0.7%	4.9%	-6.6%	-3.6%	91.7%	-6.8%
Depreciation & Amortization	19.79M	4.05M	5.32M	5.26M	5.16M	5.05M	4.94M	4.69M	4.89M
EPS Basic	2.15	2.15	0.05	-0.08	0.03	-0.16	-0.19	1.62	-0.14
EPS Diluted	2.07	2.07	0.05	-0.08	0.03	-0.16	-0.19	1.51	-0.14
Weighted Average Basic Shares	51.47M	51.47M	51.15M	51.12M	52.51M	54.30M	55.26M	54.28M	52.90M
Weighted Average Diluted Shares	53.42M	53.42M	53.13M	51.12M	53.74M	54.30M	55.26M	58.22M	52.90M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	379.81M	333.79M	280.32M	321.79M	296.40M	192.19M	127.07M	76.57M
Cost of Goods Sold	123.24M	109.63M	102.00M	112.21M	97.39M	63.12M	45.45M	32.99M
Gross Profit	256.57M	224.16M	178.32M	209.58M	199.01M	129.08M	81.61M	43.58M
Gross Profit Margin	67.6%	67.2%	63.6%	65.1%	67.1%	67.2%	64.2%	56.9%
Total Operating Expenses	281.64M	183.39M	381.69M	286.81M	228.73M	151.60M	106.14M	58.14M
Research & Development	71.43M	72.41M	81.87M	90.39M	76.53M	48.94M	30.71M	14.51M
Selling, General & Administrative	210.21M	205.50M	201.20M	196.42M	152.21M	102.66M	75.43M	43.63M
Operating Income (EBIT)	-25.07M	40.77M	-203.36M	-77.23M	-29.73M	-22.53M	-24.53M	-15.58M
Operating Margin	-6.6%	12.2%	-72.5%	-24.0%	-10.0%	-11.7%	-19.3%	-20.3%
Income Before Tax (EBT)	-21.08M	52.86M	-190.14M	-76.23M	-32.09M	-19.75M	-23.95M	-48.22M
Interest Income	9.17M	11.77M	11.87M	3.76M	160K	271K	985K	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	3.70M
Other Income/Expense	3.99M	12.09M	13.22M	997K	-2.36M	2.78M	585K	-32.64M
Net Income	-21.35M	52.55M	-190.28M	-76.61M	-30.66M	-18.71M	-21.97M	-46.76M
Income Tax Expense	271K	310K	141K	379K	-1.43M	-1.04M	-1.98M	-1.43M
Net Profit Margin	-5.6%	15.7%	-67.9%	-23.8%	-10.3%	-9.7%	-17.3%	-61.1%
EBITDA	-4.66M	60.52M	-183.54M	-61.22M	-17.84M	-12.98M	-17.39M	-11.36M
EBITDA Margin	-1.2%	18.1%	-65.5%	-19.0%	-6.0%	-6.8%	-13.7%	-14.8%
Depreciation & Amortization	20.42M	19.76M	19.82M	16.01M	11.88M	9.54M	7.14M	4.21M
EPS Basic	-0.40	1.00	-3.54	-1.44	-0.59	-0.40	-0.52	-1.31
EPS Diluted	-0.40	0.93	-3.54	-1.44	-0.59	-0.40	-0.52	-1.31
Weighted Average Basic Shares	53.29M	52.77M	53.76M	53.32M	52.24M	46.48M	42.15M	35.64M
Weighted Average Diluted Shares	53.29M	56.62M	53.76M	53.32M	52.24M	46.48M	42.15M	35.64M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.